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Abstract
Background: One of the goals of this study was to learn the coverage, safety and logistics of a
mass vaccination campaign against typhoid fever in children and adults using locally produced
typhoid Vi polysaccharide (PS) and group A meningococcal PS vaccines in southern China.
Methods: The vaccination campaign targeted 118,588 persons in Hechi, Guangxi Province, aged
between 5 to 60 years, in 2003. The study area was divided into 107 geographic clusters, which
were randomly allocated to receive one of the single-dose parenteral vaccines. All aspects
regarding vaccination logistics, feasibility and safety were documented and systematically recorded.
Results of the logistics, feasibility and safety are reported.
Results: The campaign lasted 5 weeks and the overall vaccination coverage was 78%. On average,
the 30 vaccine teams gave immunizations on 23 days. Vaccine rates were higher in those aged ≤  15
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years (90%) than in adolescents and young adults (70%). Planned mop-up activities increased the
coverage by 17%. The overall vaccine wastage was 11%. The cold chain was maintained and
documented. 66 individuals reported of adverse events out of all vaccinees, where fever (21%),
malaise (19%) and local redness (19%) were the major symptoms; no life-threatening event
occurred. Three needle-sharp events were reported.
Conclusion: The mass immunization proved feasible and safe, and vaccine coverage was high.
Emphasis should be placed on: injection safety measures, community involvement and
incorporation of mop-up strategies into any vaccination campaign. School-based and all-age Vi mass
immunizations programs are potentially important public health strategies for prevention of
typhoid fever in high-risk populations in southern China.
Background
The People's Republic of China has led the use of Vi vac-
cine as a public health tool to contain typhoid fever in
some provinces in which the disease is endemic. With Vi
vaccine proven to be efficacious in clinical trials [1,2], in
1989 the Lanzhou Institute of Biological Products began
planning for the production of Vi vaccine in cooperation
with the original developers [3]. The production followed
the specifications published by the World Health Organi-
zation (WHO) [4]. In 1995, 2 large-scale licensing rand-
omized, placebo-controlled trials in China of this locally
produced vaccine demonstrated its safety and protective
efficacy (71% and 69% protection 12 and 19 months after
vaccination, respectively) [5], [6]. During an outbreak in
1999, the vaccine was found to be 71% effective [7], sim-
ilar to the efficacy results reported in phase III trials.
Vi vaccine is currently produced by 6 vaccine institutes in
China. Some provincial and district governments have
encouraged its use through school-based campaigns
financed with reasonable user fees (e.g., US $0.30 to
$0.60 per dose). In 1996, the Guangxi Zhuang Autono-
mous Region (Guangxi Province) in southern China
introduced Vi vaccine as a public health tool for school-
aged children and for use during outbreaks. Although the
reduction in typhoid fever cases from government surveil-
lance has been reported, to date, there has been no formal
assessment of the effectiveness of the Vi vaccine use as a
public health tool.
Guangxi Province plans to expand the Vi vaccination strat-
egy beyond the school-aged children. An open cluster ran-
domized controlled Vi vaccine effectiveness evaluation
was designed and launched in 2002 with the goal of gen-
erating policy-relevant data to enable expanded use of Vi
vaccine in public health program [8]. Herein, we report
initial results on vaccine coverage, safety and logistics of
the Vi vaccine when delivered through a mass vaccination
campaign that targeted a population aged 5–60 years in a
city in Guangxi Province.
Methods
Study site and design
The vaccination campaign was carried out in Hechi Prefec-
ture (figure 1), Guangxi Province, between April 8 and
May 12, 2003. The study area (referred to in the text as
Hechi) is located 420 km northwest of the provincial cap-
ital, Nanning, and includes Jin Cheng Jiang (urban) and
Don Jiang (rural), the two most populous areas in the pre-
fecture. Agriculture is the major source of income in this
subtropical area. The average household annual income is
1,700 RMB (1$ US = 8.3 RMB). Some 80% of the popula-
tion is of the Zhuang ethnic group. Birth and death rates
were 8% and 6%, respectively, in 2001.
In recent years national child immunization program cov-
erage has been over 90% in Hechi, which has a variety of
health facilities (85 in total) including hospitals, health
centers, factory clinics and private clinics. The Hechi
Center for Disease Control (CDC) is responsible for the
collection of data on notifiable infectious diseases. In this
area, in 1995–1999, typhoid fever incidence rates were
27–153 per 100,000 residents [9] and typhoid fever
affected both school-aged children and adults.
The target population for the Vi vaccination campaign was
118,588 persons aged 5–60 years who were registered in
the project census conducted in January 2003. The study
area was divided into 107 geopolitical clusters, each
resembling a unit to be targeted in a public health pro-
gram. The mean cluster size was 1,103 persons (range:
319–2,610). Of the clusters, 77 with 85,815 persons were
in urban areas and the remaining 30, with 32,256 per-
sons, in rural areas. Of households within the clusters, the
majority (41%) lived in factory compounds, 21% in pri-
vate homes, 6% in boarding schools, 6% in government
housing and 1% in health institutions.
Clusters were randomly allocated to receive either Vi vac-
cine or a group A meningococcal (menA) vaccine, the
active control. Details of the rationale and design of this
open-cluster randomized-effectiveness trial are provided
elsewhere [10], [11]. All 107 clusters were stratifiedBMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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according to population size (large ≥  1,000 or small) and
setting (urban or rural) before randomization. The exclu-
sion criteria were pregnancy, breastfeeding, fever >37.5°C
at the time of vaccination and presence of severe chronic
diseases. The last exclusion criterion is applied to all vac-
cines in China.
Both vaccines used for this study are licensed and com-
mercially available in China; however, due to the nature
of research aspects in determining the effectiveness of the
Vi vaccine, ethical and research clearance was obtained
from the Guangxi ethical review board, the International
Vaccine Institute's institutional review board and the eth-
ical committee of the World Health Organization
(WHO). Trial information was disseminated at the com-
munity level (meetings and media) and consent was
recorded individually on the day of immunization.
Mass vaccination campaign
Promotional activities were initiated 2 months prior to
immunization and included meetings with community
leaders and campaign advertisements via local television,
loudspeakers, posters and information flyers. The mass
vaccination campaign was carried out in 4 stages. Stage I
(i.e., the pilot phase) vaccinated a few clusters in order to
test and fine-tune the system and to provide final training
for the other teams. The next stage was the large-scale vac-
cination at pre-defined vaccination posts in each cluster
according to a pre-set schedule. In stage III, the initial
mop-up, the vaccination team re-visited its corresponding
vaccination post at the cluster for 1 day. The final mop-up
(stage IV) was at a centralized vaccination center (Hechi
CDC) after the study population was again invited to be
vaccinated.
Both the Vi and the menA vaccines are licensed. They are
produced by Lanzhou Institute of Biological Products and
administered in 1-dose regimes. A Vi vaccine vial contains
two 0.5-ml doses (each with 30 µg of the purified Vi of
Salmonella enterica subspecies enterica serovar Typhi) for
both children and adults. This vaccine is administered
intramuscularly. The menA vaccine vial contains five
freeze-dried 0.2-ml doses (each is 30 µg of the purified
group A PS of Neisseria meningitidis). Each dose must be
reconstituted with 1 ml of PBS (diluent provided with the
vaccine) before subcutaneous injection.
Guangxi and Hechi CDC personnel planned, coordinated
and launched the mass campaign. Training in good clini-
cal practices (GCPs) was given to all vaccination team
Hechi in Guangxi Province, PR China Figure 1
Hechi in Guangxi Province, PR China. shows the location of Hechi and Guangxi in China.BMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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members and supervisors 1 month prior to the campaign.
The vaccines were delivered by methods that simulated
public health program conditions. One site was selected
in each cluster (school, health facility, factory or locations
such as intersections and squares) to become the vaccina-
tion posts. Table 1 depicts the type of personnel involved,
responsibilities and numbers needed during the
campaign.
Each team was expected to vaccinate about 200 persons
each day and to cover 3 or 4 clusters in 20 days. Identifi-
cation cards similar to those used in the local expanded
program of immunization (EPI) were distributed to each
household 1 month before vaccination. The cards had
identifying information and a study number that corre-
sponded to the household's date and time of vaccination.
In order to avoid errors in vaccine allocation, each vaccine
team delivered only one vaccine. Those registered in the
project census were vaccinated and recorded. However,
persons not registered in the project census were offered
menA vaccine at the end of the campaign.
Each vaccination team was equipped with: 1 or 2 cold
boxes, injecting material, emergency kits, 1 safety disposal
box and stationary. All eligible participants were listed in
a vaccination record book available at the vaccine posts.
Those who came for immunization and gave informed
consent were assessed for eligibility by the vaccination
team and vaccination status, regardless of received or not
received, was recorded in the vaccination record book,
which was later entered into a database. Vaccination cov-
erage was calculated from this database.
All aspects of safety for each of the study vaccines were
emphasized and the vaccination teams received intensive
training. Two particular aspects were monitored: safe
injection practices and adverse events (AE). Proper vac-
cine administration (intramuscular for typhoid Vi and
subcutaneous for menA), aseptic injection technique and
injection safety (not recapping and disposing of used nee-
dles into safety boxes) were closely monitored by supervi-
sors and external observers. Team members were
instructed to report all accidents involving sharps and
needles to their supervisor. The complete incineration of
used safety boxes was monitored by the Hechi CDC staff.
Safety of the vaccines was monitored systematically. All
vaccinees were asked to remain in the vaccination posts
for at least 15 minutes after vaccination to be monitored
for any immediate serious adverse event (SAE) by the phy-
sician of the vaccination team. 535 randomly chosen vac-
cinees were visited for 3 consecutive days after vaccination
by the project personnel for solicited adverse event sur-
veillance. Unsolicited (passive) adverse event surveillance
was carried out for one month following vaccination by
having all healthcare facilities in the study area to report
signs and symptoms of patients with history of receiving
the vaccine, or hospitalization cases of the vaccinees to
Hechi CDC. Physicians attending the patients were asked
to fill in a form for all the cases with causality specified.
Inadvertent vaccination of pregnant women was to be
reported passively during the vaccination campaign; these
cases would be followed until delivery. Deaths of study
participants are being ascertained through established
mortality surveillance by Hechi CDC, which gathers infor-
mation from death certificates and cremation and hospi-
Table 1: Human resources involved in the Hechi, China, typhoid fever vaccine campaign 2003
Personnel Function Number
Vaccine team (30 teams)*
Leaders (physicians) Overall responsible for cluster vaccination; daily collection of vaccines and supplies; 
treat SAE
30
Nurses Vaccinator 43
Other health workers Recorder 24
Non-health workers Recorder 9
Community helpers Facilitated immunization process; liaison between community and Hechi Center for 
Disease Control
78
Other
Storage room Maintained cold chain 4
Data management Data entry of vaccine records 6
Field health workers SAE 3-day home visit 3
Drivers 3
Supervisors Assured adherence to standard operating procedures 7
NOTE: The research-component of the project is not included
* Each team had a leader, vaccinator, recorder and community helper.BMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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tal records for the 2-year follow-up period. Project
personnel reviewed all incoming forms to determine the
causality and when unclear, a trial clinical monitor
assisted in reviewing the forms.
For both vaccines the manufacturer recommends storage
temperatures of 2–8°C. All supplies, including the vac-
cines, were stored at the logistic hub at Hechi CDC: a 3 ×
12 m2 room equipped with 8 refrigerators and 1 freezer.
The number of vaccine vials and supplies distributed to
each team was recorded daily to calculate vaccine usage
and wastage. The maintenance of the cold chain was veri-
fied at all stages from the time the vaccine left the manu-
facturer until it reached the vaccination posts. Maximum/
minimum (max/min) thermometers and battery-auto-
mated temperature recorders were used to monitor the
vaccine temperature during transportation and storage.
Regular thermometers in cold boxes were used at the vac-
cine posts. Temperatures were documented daily in tem-
perature charts – twice for stored vaccines and 3 times for
the cold boxes.
Results
The vaccination campaign lasted 31 workdays, during
which 53 clusters received typhoid Vi vaccine and 54 the
menA PS vaccine. Thirty teams gave immunizations on an
average of 23 days, covering a target population of
118,588 in 107 clusters. Overall, 96,504 people came to
the vaccination posts and 92,476 were immunized, yield-
ing an overall vaccine coverage of 78%. In all, 25,605 per-
sons were not vaccinated: 80% (20,472) did not appear
for immunization. Table 2 summarizes reasons for not
being vaccinated. 80% of the non-immunized did not
show-up and 13% were excluded at time of vaccination
(serious illness, lactation, pregnancy or fever).
The vaccine coverage was 77% and 80% for Vi vaccine and
menA vaccine, respectively. Figure 2 shows household
locations (mapped by global positioning system technol-
ogy) and magnitude of coverage by urban and rural area
(and by cluster). As shown in figure 3, the highest vaccina-
tion coverage (≈ 90%) was achieved in children less than
15 years of age and was lowest in adolescents (15–19
years) and young adults (20–29 years), reaching 70%.
Coverage by gender was similar: 79% in males and 82%
in females. High vaccine coverage rates (92.5%) occurred
in clusters that corresponded to schools. Figure 4 illus-
trates vaccine coverage by program stage: 74% (range:
56% – 92%) of the overall coverage was achieved in the
first two phases of the vaccination campaign. During
mop-up (phases III and IV), 5,269 persons (17% of the
total remaining target population) were vaccinated,
achieving final coverage of 78% (range: 65% – 93%).
Stages I and II lasted 4 days and 5 days (range: 2–9) per
cluster, respectively. The initial mop-up stage (stage III)
required 4 days and the final mop-up (stage IV) was
performed in 3 days. Both of these stages were preceded
by 1-day with re-invitation activities.
Three needle-stick injuries were reported during the mass
vaccination campaign. All cases happened to the vaccina-
tors of the team. One case occurred during crowded hours
at the vaccination post, while two cases occurred due to
mishandling of the sharp disposal box. The 3 persons
exposed to blood were tested for hepatitis B surface anti-
gen (HBsAg) antibodies and immediately given 1 dose of
hepatitis B vaccine according to the local guidelines. No
further doses were necessary as all 3 were anti-HBsAg
positive.
No life-threatening immediate AE were observed. The sur-
veillance system did identify 1 serious AE; however, this
auto-limited febrile case which required hospitalization
was not severe and the patient recovered in 12 hours. Of
the 413 persons interviewed for solicited AE, 408 were
surveyed on all 3 days, and no SAE were reported. In total
129 (38 Vi and 91 menA) AEs determined to be caused by
the vaccine were reported from 66 individuals (26 Vi and
40 menA), consisting mainly in fever (21% Vi and 19%
menA; ranging between 37.5°C to 39.5°C), malaise (19%
Vi and 10% menA), and/or minor rash (19% Vi and 5%
menA) around the site of injection. In all, 3,430 hospital-
izations were reported 1 month after the immunizations.
Of these persons, 300 had been immunized during the
campaign. The trial clinical monitor determined that
Table 2: Reasons for not being vaccinated during the vaccine campaign
Reason Pregnancy Lactation Fever Serious 
disease
Refusal* Did not 
show-up
Vaccinated 
previously
Total
No. person 533 714 143 1,851 788 20,472 1,104 25,605
( % ) 231738 0 41 0 0
* at the time of seeking consentBMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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none of the hospitalizations (the majority were scheduled
surgeries) were related to vaccine injections.
The Lanzhou Institute initially shipped 60,000 doses of Vi
vaccine and 80,000 doses of menA vaccine to the study
site by refrigerated (2–4°C) truck monitored by max/min
thermometer. Once the temperature reached 14°C for
approximately 3 hours. The vaccines were stored in cold
rooms at the Guangxi CDC for 6 days where temperature
ranged from 2°C to 8°C. On March 29, 2003, the vaccines
were sent to the Hechi CDC in a refrigerated truck. This
420-km journey took 6 hours. The cold chain (monitored
by battery-powered temperature recorder) was main-
tained between 4°C and 9°C. At the Hechi CDC, all
140,000 vaccine doses had temperature readings of 2°C
to 11°C. The mean temperature recorded in the field was
4.2°C (range: 1.8°C – 12°C). In all, 26 vials of Vi vaccine
were discarded due to freezing.
Wastage based on breakage, missing at inventory and
unused opened vials was higher as expected for the 5-dose
vial of the menA vaccine vial than for the Vi vaccine
(12.8% vs. 9.2%., respectively). In conformity with the
product information sheet, vials of menA vaccine were
discarded within 1 hour of opening if not used. At the end
of the campaign the unused doses of both vaccines were
shipped to the Hechi CDC headquarters so they could be
used elsewhere.
The number of personnel required during the campaign is
shown in table 1. The majority were volunteer community
members. Transportation from the Hechi CDC to the vac-
Vaccine coverage in Hechi Figure 2
Vaccine coverage in Hechi. shows the vaccine coverage by cluster and household locations in Hechi. Darker the color, 
higher the coverage is. Boundary of the city is also shown.BMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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cination posts required a variety of transport: foot, bicy-
cles and motorized vehicles (motorcycles, cars, buses or
ambulances).
Conclusion
The results verify that a mass vaccination campaign with
the 1-dose parenteral Vi vaccine or the menA vaccine,
which targeted both school-aged children and adults in
Hechi, south China, was logistically feasible and safe. An
important coverage rate was attained with no major dis-
ruption to the normal EPI or other health activities.
In general, there are three main concerns when launching
population-based large-scale vaccination campaigns: (1)
resources, (2) safety and (3) cost. Especially in developing
countries, there is the need to identify resources outside
the well-established local vaccine delivery system (usually
the EPI program). The Hechi campaign illustrates that an
existing healthcare system can deliver vaccines to large
populations in a fairly short period of time. Community
members can play a key role in the success of promotional
activities and delivery of vaccines when an entire city is
targeted.
The Hechi campaign monitored and recorded safety sys-
tematically and in depth. No life-threatening serious AE
were associated with either vaccine. No reported AE (solic-
ited or not) were serious and all patients recovered
quickly. Use of safety boxes was introduced for the first
time in Hechi during this mass vaccination campaign.
Despite instruction on safe handling of sharps, 3 needle-
stick injuries were recorded. For future mass vaccination
campaigns, including routine EPI activities, safe injection
practices must be introduced and emphasized to prevent
unnecessary accidents and spread of blood-borne
diseases.
A mop-up strategy increased the coverage by 9.6% on
average in the lower-coverage clusters and by 0.7%
increase in the higher-coverage clusters. Because mop-up
strategies imply the need for additional time and costs,
this strategy should be planned in advance. Adult cover-
Vaccine coverage by age group Figure 3
Vaccine coverage by age group. shows the coverage of each vaccine by age group.BMC Public Health 2005, 5:49 http://www.biomedcentral.com/1471-2458/5/49
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age was slightly lower than that of children, but a 70%
coverage indicates the ability to reach adults during a vac-
cination campaign. The comprehensive vaccine safety sur-
veillance system, implemented within the existing Hechi
health facilities, was useful. Post-licensure monitoring can
address many issues regarding safety, such as: uncommon
AE, incorrect storage or administration procedures and
dissemination of information to the public to maintain
confidence in the scheme [12].
The cost-effectiveness of the use of Vi vaccine will be ana-
lyzed at the end of the study. However, because the vac-
cine is locally produced, it seems reasonable to anticipate
that unlike EPI vaccines, cost savings can be achieved by
reduced transportation costs and in-country production
of the vaccine. In an urban area of Vietnam, a locally pro-
duced oral cholera vaccine distributed through mass
immunization was found to be affordable if introduced in
a public health program [13]. In countries, with decentral-
ized health systems, such as China, public health sector
introduction or expansion of the use of Vi vaccine can be
initiated and financed by local governments.
Mass immunization is considered the most logical control
strategy, outside the EPI program, in settings that typically
manifest high incidences of disease or in populations
exposed to predictable outbreaks [14]. Besides school-
based immunization programs, all-age (5–60 years) Vi
Cluster vaccine coverage by campaign stages Figure 4
Cluster vaccine coverage by campaign stages. shows the cluster vaccine coverage by campaign stages.Publish with BioMed Central    and   every 
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mass vaccinations are potentially an important public
health strategy to prevent typhoid fever in high-risk popu-
lations in southern China. Follow-up of the randomized
double-blind placebo-controlled trials of Vi vaccine indi-
cate that vaccine protection of 50% lasts for 3 years (man-
uscript in preparation). The usefulness of Vi vaccine may
be further advanced with the development of Vi conjugate
vaccine [15]. We anticipate that the vaccine cost results,
together with cost-effectiveness analysis of the Hechi pro-
gram, will complement the above findings and provide
objective information to assist policymakers who are
increasingly confronted with juggling decisions regarding
the use of a growing list of available vaccines while deter-
mining health priorities, often under severe budgetary
constraints.
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